Treatment Pattern and Outcome of Newly Diagnosed Multiple Myeloma Patients in a Resource-Limited Setting

Document Type : Research Articles

Authors

1 Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.

2 Beacon Hospital, Petaling Jaya, Selangor, Malaysia.

3 KPJ Ampang Puteri Specialist Hospital, Ampang, Selangor, Malaysia.

4 Universiti Malaya Medical Center, Kuala Lumpur, Malaysia.

Abstract

Background: Multiple myeloma is the third most common hematologic malignancy in Malaysia. The introduction of novel agents over the past decades has improved patient outcome and survival substantially. However, these agents incur significant economic burden, thus leading to limited use in less developed countries. This study aims to report on the real-world treatment pattern and outcome of newly diagnosed multiple myeloma (NDMM) patients from a resource-constraint setting. Methods: This is a retrospective study on NDMM patients diagnosed between 1 January 2008 and 31 December 2022 in a single academic center. Patients’ demographic and treatment details were included for analysis of progression free survival (PFS) and overall survival (OS). Results: One hundred and thirty-six NDMM patients with a median age of 64.0 years (ranged from 38 to 87 years old) were included. Bortezomib-containing regimens were the most commonly used induction agent, followed by thalidomide. Almost half of the patients (47.1%) achieved very good partial response (VGPR) or complete remission (CR), while 31.6% achieved partial response (PR). Bortezomib containing regimen was associated with significantly deeper and more rapid response, (p=0.001 and p=0.017, respectively) when compared to other agents. Only 22.8% of these patients proceeded to upfront autologous haematopoietic stem cell transplantation.  The median OS and PFS were 60.0 months and 25.0 months, respectively. Best initial response and upfront autologous stem cell transplantation (ASCT) were significantly associated with better PFS. Conclusion: Achieving at least a VGPR significantly associated with better outcome in NDMM patients. In a resource constrain country, we recommend incorporating bortezomib in the induction therapy followed with an upfront ASCT.

Keywords

Main Subjects

Asian Pacific Journal of Cancer Prevention
Volume 25, Issue 2
February 2024
Pages 595-601

Files

History

  • Receive Date: 03 October 2023
  • Revise Date: 20 December 2023
  • Accept Date: 22 February 2024

Share

How to cite

Statistics